Darmadi, D. (2024) “An Efficacy and Safety Comparison of Regorafenib and Nivolumab in Unresectable Hepatocellular Cancer Patients: A Systematic Review”, Acta Medica Academica, 53(1), pp. 46–58. doi: 10.5644/ama2006-124.443.